Oligometastatic Prostate Cancer Treatment Outcomes from Five Chinese Centers

Yujie Dong's multicenter retrospective study analyzes 160 oligometastatic prostate cancer patients treated between May 2010 and May 2023. The data compares perioperative and oncological outcomes for patients receiving neoadjuvant hormonal therapy plus robot-assisted radical prostatectomy versus standard therapy alone.

Use Cases

• Compare operative time and blood loss metrics between NHT and standard therapy groups to assess surgical efficiency.
• Analyze positive surgical margin rate and pathological downstaging in T-stage to evaluate treatment impact on pathology.
• Model biochemical progression-free survival (bPFS) and overall survival (OS) with subgroup analysis for biopsy Gleason score ≥8.
• Assess the frequency of subsequent treatments and ADT-related adverse events across patient cohorts.

Strengths

• Data from 160 patients provides a substantive cohort for comparative analysis of two treatment protocols.
• Multicenter design incorporates records from five Chinese medical centers, reducing single-institution bias.
• Median postoperative follow-up of 52 months allows for medium-term assessment of oncological outcomes like bPFS and OS.

Limitations

• The 15.3 KB file size indicates the dataset is a summary table or document, not a raw patient-level data table.
• As a retrospective study, the data is observational and subject to selection bias and confounding factors.
• Sample data and column definitions are unavailable, limiting immediate analysis of individual patient variables.

Provenance

Source

Yujie Dong via figshare.

Collection Method

Multicenter retrospective study of medical records.

Time Range

May 2010 to May 2023.

Freshness

Data covers treatments up to May 2023, with the record last updated in March 2026.

Geography

Five medical centers in China.